CN116474176A - 一种适用于人体自然腔道的润滑液及其应用 - Google Patents
一种适用于人体自然腔道的润滑液及其应用 Download PDFInfo
- Publication number
- CN116474176A CN116474176A CN202310274339.XA CN202310274339A CN116474176A CN 116474176 A CN116474176 A CN 116474176A CN 202310274339 A CN202310274339 A CN 202310274339A CN 116474176 A CN116474176 A CN 116474176A
- Authority
- CN
- China
- Prior art keywords
- extract
- human body
- lubricating fluid
- natural
- achillea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001050 lubricating effect Effects 0.000 title claims abstract description 49
- 239000012530 fluid Substances 0.000 title claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 49
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 241000722941 Achillea Species 0.000 claims abstract description 16
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 15
- 239000000230 xanthan gum Substances 0.000 claims abstract description 15
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 15
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 241001570521 Lonicera periclymenum Species 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 244000167230 Lonicera japonica Species 0.000 claims description 5
- 235000017617 Lonicera japonica Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 240000000073 Achillea millefolium Species 0.000 claims description 4
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 241000157835 Gardenia Species 0.000 claims 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 239000000419 plant extract Substances 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 230000001760 anti-analgesic effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000037380 skin damage Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 244000111489 Gardenia augusta Species 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- -1 hydrogen ions Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZQPVHVKWCGZNDW-NVYKSAHZSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZQPVHVKWCGZNDW-NVYKSAHZSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001113925 Buddleja Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940105017 achillea millefolium extract Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- NBGJGWFIDMDCAW-UHFFFAOYSA-N egonol-beta-gentiobioside Natural products C=1C=2C=C(C=3C=C4OCOC4=CC=3)OC=2C(OC)=CC=1CCCOC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O NBGJGWFIDMDCAW-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于润滑液技术领域,公开了一种适用于人体自然腔道的润滑液。本发明所述适用于人体自然腔道的润滑液中透明质酸/透明质酸钠、黄原胶、蓍草提取液、栀子提取液、忍冬提取液和枸橼酸的质量体积比为0.1‑0.7g:0.3‑1.1g:5‑9ml:1.5‑1.9ml:1.2‑4ml:0.15‑0.3g,该润滑液结合不同植物提取物的复合作用,广谱抗菌,还具有消炎镇痛作用,可避免因皮肤破损引起的不适。
Description
技术领域
本发明涉及润滑液技术领域,具体是涉及一种适用于人体自然腔道的润滑液及其应用。
背景技术
目前市面上的人体润滑液主要分为水基、油基、硅基三种。其中,油性润滑液主要成分中除水分外还包含油脂,不易清洗,且不环保,还会引起局部皮肤的过敏等现象;硅树脂润滑液,比较浓稠,效果比较持久,但是其对同类材质的物品有一定的伤害,不能和硅树脂情趣用品一起使用,且这油基、硅基润滑液有异味,影响使用体验。
水溶性润滑液属于环保产品,符合国际潮流,具有使用自然方便、易清洗易吸收、可以和乳胶安全套同时使用等优点,且一般不会引起过敏,具有无可比拟的优势。然而,市面上的很多润滑液含有的抗菌剂如尼泊金酯类、苯氧乙醇类、三氯生类、苯扎氯铵,频繁使用会影响肌肤屏障健康不耐受,使角质细胞结构松散,导致肌肤粗糙,易敏感,破坏人体腔道菌群平衡或影响免疫、神经及生殖系统等,还存在长期使用可能致癌、长久储存产生有毒物质等危害。基于这些原因,有的研究者使用纳米银作为替代防腐剂,但其应用于水溶性润滑液难以均匀分散,不能达到预期效果。
相较于其他抗菌防腐剂,植物提取物受个体差异影响的概率更低,安全有效,且具有一定药用作用。然而,植物提取物成分复杂,单独使用一种植物提取物难以达到理想效果,随意组合又有可能使用不当,甚至达到一加一小于二的效果,因此,目前成功应用植物提取物作为润滑液抗菌防腐剂的产品较少。
发明内容
本发明的目的是为了克服上述背景技术的不足,提供了一种适用于人体自然腔道的润滑液及其应用,该润滑液结合不同植物提取物的复合作用,广谱抗菌,还具有消炎镇痛作用,可避免因皮肤破损引起的不适。
为达到本发明的目的,本发明适用于人体自然腔道的润滑液中包含透明质酸/透明质酸钠、黄原胶、蓍草提取物、栀子提取物、忍冬提取物和枸橼酸。
其中,酸性环境下,黄原胶可以与枸橼酸提供的氢离子发生静电作用形成结构致密的络合物,可以实现对提取液的包覆,防止提取物质氧化变质,使其性能稳定,同时具有凝胶形成性、生物降解性和生物相容性。
透明质酸是构成人体结缔组织的主要成分,在体内发挥保水、维持细胞外空间、调节渗透压、润滑、促进细胞修复的重要生理功能。透明质酸分子中含有大量的羧基和羟基,在水溶液中可形成分子内和分子间的氢键,这使其具有强大的保水作用,作为细胞外基质的主要成分,透明质酸在组织再生、炎症反应和血管生成等皮肤伤口修复阶段具有关键作用。透明质酸还具有独特的智能化保湿能力,在干燥缺水的时候,能锁住水分,而在湿润的情况下,又不会吸附太多的水导致潮湿。
蓍草提取物中含有酸性乙醇、酸性乙酸乙酯及酸性乙醚,对金黄色葡萄球菌、乙链球菌、大肠杆菌及绿脓杆菌等具有抑制作用。蓍草总酸对炎症早期的毛细管扩张及通透性增高以及炎性渗出和水肿有明显作用,具有消炎镇痛止痛的功效。
栀子提取物含有十几种环烯醚萜甙类化合物,包括栀子甙、羟异栀子甙、京尼平京尼平-1-β、龙胆双糖甙、栀子甙酸、京尼平等,可以抗菌消炎,尤其能抑制皮肤真菌。
忍冬提取物所含的木犀草素可抑制金黄色葡萄球菌、绿脓杆菌、白色念珠菌及伤寒杆菌等,具有抗菌、消炎、抗感染的作用。
黄原胶分子侧链带负电荷,与带有正电荷的枸橼酸发生静电作用,形成螺旋复合凝聚物,当复合凝聚物沉降到分子表面就实现对功能物质的包覆作用,避免其氧化。
优选地,在本发明的一些实施例中,所述适用于人体自然腔道的润滑液按重量份数计,包含透明质酸/透明质酸钠0.1-0.8份,黄原胶0.2-1.5份,蓍草提取液4-10份,栀子提取液1-2份,忍冬提取液0.8-4份,枸橼酸0.1-0.4份。
进一步优选地,在本发明的一些实施例中,所述适用于人体自然腔道的润滑液中透明质酸/透明质酸钠、黄原胶、蓍草提取液、栀子提取液、忍冬提取液和枸橼酸的质量体积比为0.1-0.7g:0.3-1.1g:5-9ml:1.5-1.9ml:1.2-4ml:0.15-0.3g。
更进一步优选地,在本发明的一些实施例中,所述适用于人体自然腔道的润滑液中透明质酸/透明质酸钠、黄原胶、蓍草提取液、栀子提取液、忍冬提取液和枸橼酸的质量体积比为0.1-0.3g:0.4-1.0g:6-8ml:1.6-1.8ml:1.8-3.4ml:0.15-0.25g。
进一步地,在本发明的一些实施例中,所述蓍草提取物的制备方法为:将干燥的蓍草粉碎成粉末,过筛,混匀,取粗粉和65-75%乙醇,按料液比1:15-25,超声提取半小时,过滤,滤液离心即得蓍草提取物。
进一步地,在本发明的一些实施例中,所述栀子提取物的制备方法为:将栀子药材粉碎,过筛,取栀子粗粉和65-75%乙醇,按料液比1:5-15,50-60℃回流提取1-3h,滤液回收浓缩得浓缩液。
优选地,在本发明的一些实施例中,所述浓缩液与栀子粗粉的体积质量比为1.5-2.5ml:1g。
进一步地,在本发明的一些实施例中,所述忍冬提取物的制备方法为:将干燥样品粉碎得忍冬粉末,加入8-10倍量的水,混匀后60-85℃浸提80-100min,过滤,滤渣用忍冬粉末重量5-8倍的水60-85℃浸提45-75min,合并两次提取液,往提取液中加入醋酸,醋酸的添加量为忍冬两次提取液重量和的10-20%,在50-65℃下静置2-5h后室温静置,过滤沉淀,得忍冬提取液。
本发明为了开发对人体使用无负担、安全稳定的润滑液,摒弃了传统防腐剂及其他化学消炎杀菌的原料,以生物相容性和生物可降解性植物提取物为有效成分,采用纯天然配方,配方简单。
本发明适用于人体自然腔道的润滑液在保证产品安全抗过敏的前提下保湿、润滑、减少摩擦,并有抗菌消炎作用,减少了过敏机率的发生,用于避孕套中也不会与避孕套的乳胶成分发生化学反应,不会导致避孕套破损。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。应当理解,以下描述仅仅用以解释本发明,并不用于限定本发明。
本文中所用的术语“包含”、“包括”、“具有”、“含有”或其任何其它变形,意在覆盖非排它性的包括。例如,包含所列要素的组合物、步骤、方法、制品或装置不必仅限于那些要素,而是可以包括未明确列出的其它要素或此种组合物、步骤、方法、制品或装置所固有的要素。
连接词“由…组成”排除任何未指出的要素、步骤或组分。如果用于权利要求中,此短语将使权利要求为封闭式,使其不包含除那些描述的材料以外的材料,但与其相关的常规杂质除外。当短语“由…组成”出现在权利要求主体的子句中而不是紧接在主题之后时,其仅限定在该子句中描述的要素;其它要素并不被排除在作为整体的所述权利要求之外。
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1至2”、“1至2和4至5”、“1至3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。
单数形式包括复数讨论对象,除非上下文中另外清楚地指明。“任选的”或者“任意一种”是指其后描述的事项或事件可以发生或不发生,而且该描述包括事件发生的情形和事件不发生的情形。
说明书和权利要求书中的近似用语用来修饰数量,表示本发明并不限定于该具体数量,还包括与该数量接近的可接受的而不会导致相关基本功能的改变的修正的部分。相应的,用“大约”、“约”等修饰一个数值,意为本发明不限于该精确数值。在某些例子中,近似用语可能对应于测量数值的仪器的精度。在本申请说明书和权利要求书中,范围限定可以组合和/或互换,如果没有另外说明这些范围包括其间所含有的所有子范围。
本发明要素或组分前的不定冠词“一种”和“一个”对要素或组分的数量要求(即出现次数)无限制性。因此“一个”或“一种”应被解读为包括一个或至少一个,并且单数形式的要素或组分也包括复数形式,除非所述数量明显只指单数形式。
此外,下面所描述的术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不是必须针对相同的实施例或示例。而且,本发明各个实施方式中所涉及到的技术特征只要彼此之间未构成冲突就可以相互组合。
本发明具体实施方式中植物提取物的提取方法如下:
1.蓍草提取物:将干燥的蓍草粉碎成粉末,通过二号筛,并混合均匀。取粗粉4g,70%乙醇提取液,料液比1:20,置锥形瓶中,密塞,冷浸,超声提取半小时,用干燥滤器迅速滤过,滤液离心即得蓍草提取物。
2.栀子提取物:栀子药材粉碎,过4号筛网,取栀子粗粉5g,60%乙醇提取液,料液1:10,55℃回流提取2h,滤液回收浓缩至10ml。
3.忍冬提取物:将干燥样品粉碎得忍冬粉末,取5g粉末,加入忍冬粉末重量8-10倍的水,混匀后60-85℃浸提80-100min,过滤,滤渣用忍冬粉末重量5-8倍的水60-85℃浸提45-75min,合并两次提取液;将提取液中加入醋酸,醋酸的添加量为忍冬提取物液重量的10-20%,在50-65℃下静置2-5h,然后室温静置,过滤沉淀,得忍冬提取液。
实施例1
称取透明质酸钠0.05g加30gml水放置半小时左右,用玻璃棒或磁力搅拌器溶解。
称黄原胶0.6g加30ml水放置半小时左右,用玻璃棒或磁力搅拌器溶解。
取蓍草提取液8ml,栀子提取液1.6ml,忍冬提取液1.8ml混合均匀后,倒入溶解的透明质酸钠溶液中,最后再与黄原胶溶液混匀,加入枸橼酸0.2g,加水定容至100ml。
实施例1-30的润滑液配方组成如下表1所示。
表1实施例1-30的润滑液配方组成
测试例1
保湿率的测定:称取一定量润滑液样品放置在装有硅酸干凝胶的低湿度干燥器中,间隔24小时取出称量。由实验前后样品的质量差,计算出样品的保湿率。
保湿率=(m1-m2)/m1×100%,其中,m1为样品实验前质量(g),m2为样品实验后质量(g)。
测定结果如表2所示。
表2保湿率测定结果
根据以上数据可知,透明质酸钠对样品保湿具有重要作用,其保湿率在一定范围内随着透明质酸钠浓度升高而升高,当透明质酸钠的浓度到一定比例后,保湿效果不再增加。
测试例2
样品稳定性的测定:将样品常温放置,在第1、3、6个月取样观察外观、黏度,并检测样品的初始污染菌。
具体方法为取10g样品,加入200ml灭菌生理盐水,充分混匀,得到一个生理盐水样液。后取上清液作菌落计数,共接种5个平皿,每个平皿中加1ml样液,然后用冷却至45℃左右的熔化的营养琼脂培养基15-20ml,倒入每个平皿内混合均匀,待琼脂凝固后翻转平皿置35℃±2℃培养7天,以上相同的操作倒入沙氏琼脂培养基,翻转平皿置25℃±2℃培养7天,计算平板上的菌落总数。
细菌和真菌菌落总数(cfu/g)=5块营养琼脂培养基平板上的菌落总数×稀释度/5。
测定结果如表3所示。
表3样品稳定性测定结果
以上数据表明,黄原胶和枸橼酸协同作用会对样品起到稳定作用,缺少一种都会导致样品性状不稳定,但不是添加量越多越好,例8黄原胶添加量较其他配比量多,例24柠檬酸添加量较其他配比量多,但从抑菌性来看并无明显优势。
本发明的三类提取液足以起到抗菌效果,保存六个月外观无变化,但缺少其中一种会导致抗菌性不足,使用本发明的组分互配才能取得理想的抗菌效果。
测试例3
样品抑菌性的测定:将试验菌(金黄色葡萄球菌、大肠杆菌、白色念珠菌)斜面培养物用PBS洗下,制成1×104~9×104浓度的cfu/ml的菌悬液。取100μl菌悬液加入到5ml混有0.5ml样品的PBS溶液中,分别吸取0.5ml,置于营养琼脂培养基(细菌)或沙氏琼脂培养基(醉母菌)中,倒扣培养,35℃±2℃培养48h(细菌)或72h(酵母菌),作活菌菌落计数。
抑菌率=(对照样品平均菌落数-被试样品平均菌落数)/对照样品平均菌落数×100%。
测定结果如表4所示。
表4样品抑菌性测定结果
根据上述数据可知,同时添加适宜量本发明三种提取液的抑菌率均≥90%,具有强抑菌性。然而,仅添加其中两种提取液抑菌率≥50,仅仅是具有一定抑菌效果,远不如三种提取液复合作用抑菌效果显著,这三种提取液添加量过少,抑菌效果也较差。
测试例4
样品致敏性的测定:测试方法为豚鼠最大剂量实验,使用0.9%氯化钠注射液和芝麻油双浸提,观察敷贴试验的皮肤反应情况。共分为等级0-3,0等级为无致敏反应,等级越大致敏反应越明显。
测定结果如表5所示。
表5样品致敏性测定结果
上述经过说明本发明润滑液中无致敏物质,绿色安全。
测试例5
润滑液对安全套影响测试:取没有涂抹润滑液和涂抹润滑液的橡胶避孕套放入老化箱,50℃放置90天,取出做拉力测试。涂抹的润滑液为实施例23配方,平行测试5组。
测定结果如表6所示。
表6样品稳定性测定结果
由以上测试数据可看出,拉力值稳定,说明本发明的润滑液对安全套材质性能无影响。
本领域的技术人员容易理解,以上所述仅为本发明的实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种适用于人体自然腔道的润滑液,其特征在于,所述适用于人体自然腔道的润滑液中包含透明质酸/透明质酸钠、黄原胶、蓍草提取物、栀子提取物、忍冬提取物和枸橼酸。
2.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述适用于人体自然腔道的润滑液按重量份数计,包含透明质酸/透明质酸钠0.1-0.8份,黄原胶0.2-1.5份,蓍草提取液4-10份,栀子提取液1-2份,忍冬提取液0.8-4份,枸橼酸0.1-0.4份。
3.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述适用于人体自然腔道的润滑液中透明质酸/透明质酸钠、黄原胶、蓍草提取液、栀子提取液、忍冬提取液和枸橼酸的质量体积比为0.1-0.7g:0.3-1.1g:5-9ml:1.5-1.9ml:1.2-4ml:0.15-0.3g。
4.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述适用于人体自然腔道的润滑液中透明质酸/透明质酸钠、黄原胶、蓍草提取液、栀子提取液、忍冬提取液和枸橼酸的质量体积比为0.1-0.3g:0.4-1.0g:6-8ml:1.6-1.8ml:1.8-3.4ml:0.15-0.25g。
5.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述蓍草提取物的制备方法为:将干燥的蓍草粉碎成粉末,过筛,混匀,取粗粉和65-75%乙醇,按料液比1:15-25,超声提取半小时,过滤,滤液离心即得蓍草提取物。
6.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述栀子提取物的制备方法为:将栀子药材粉碎,过筛,取栀子粗粉和65-75%乙醇,按料液比1:5-15,50-60℃回流提取1-3h,滤液回收浓缩得浓缩液。
7.根据权利要求6所述的适用于人体自然腔道的润滑液,其特征在于,所述浓缩液与栀子粗粉的体积质量比为1.5-2.5ml:1g。
8.根据权利要求1所述的适用于人体自然腔道的润滑液,其特征在于,所述忍冬提取物的制备方法为:将干燥样品粉碎得忍冬粉末,加入8-10倍量的水,混匀后60-85℃浸提80-100min,过滤,滤渣用忍冬粉末重量5-8倍的水60-85℃浸提45-75min,合并两次提取液,往提取液中加入醋酸,醋酸的添加量为忍冬两次提取液重量和的10-20%,在50-65℃下静置2-5h后室温静置,过滤沉淀,得忍冬提取液。
9.权利要求1-8任一项所述适用于人体自然腔道的润滑液,其特征在于,所述适用于人体自然腔道的润滑液用于避孕套中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310274339.XA CN116474176A (zh) | 2023-03-21 | 2023-03-21 | 一种适用于人体自然腔道的润滑液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310274339.XA CN116474176A (zh) | 2023-03-21 | 2023-03-21 | 一种适用于人体自然腔道的润滑液及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116474176A true CN116474176A (zh) | 2023-07-25 |
Family
ID=87220374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310274339.XA Pending CN116474176A (zh) | 2023-03-21 | 2023-03-21 | 一种适用于人体自然腔道的润滑液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116474176A (zh) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5878747A (en) * | 1993-12-28 | 1999-03-09 | Fuji Latex Co., Ltd. | Condom coated with acidic polysaccharides |
CN1517326A (zh) * | 2002-07-12 | 2004-08-04 | 范崔生 | 栀子环烯醚萜总提物及其制备方法和用途 |
CN102846690A (zh) * | 2012-08-29 | 2013-01-02 | 江苏康宝医疗器械有限公司 | 阴道保健润滑液及其制备方法 |
CN103083733A (zh) * | 2013-02-19 | 2013-05-08 | 华熙福瑞达生物医药有限公司 | 一种医用体腔器械导入水性润滑剂 |
US20150264935A1 (en) * | 2014-03-19 | 2015-09-24 | Yi-Shou Chang | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same |
CN105999426A (zh) * | 2016-07-26 | 2016-10-12 | 广东诺丝科技股份有限公司 | 一种透明质酸水溶性人体润滑液 |
CN106267381A (zh) * | 2016-07-12 | 2017-01-04 | 东莞市万佳医疗科技有限公司 | 体腔导入润滑液及其制备方法 |
KR20170019183A (ko) * | 2015-08-11 | 2017-02-21 | (주)헵틸와이 | 산화 다당류 및 친수성 고분자 함유 코팅층을 포함하는 의료용 카테터 및 그 제조방법 |
CN108079385A (zh) * | 2017-12-20 | 2018-05-29 | 江苏省健尔康医用敷料有限公司 | 高均一性灭菌医用润滑剂 |
CN108785358A (zh) * | 2018-08-27 | 2018-11-13 | 维康腾达生物科技有限公司 | 一种金银花提取物的制备方法 |
CN109010932A (zh) * | 2018-08-23 | 2018-12-18 | 太仓怡泰霖智能科技有限公司 | 一种对妇科炎症有预防效果的热感水溶性人体润滑液 |
CN110393825A (zh) * | 2018-04-25 | 2019-11-01 | 北京为纳百川商贸有限公司 | 一种人体润滑液 |
CN112587294A (zh) * | 2020-12-31 | 2021-04-02 | 威乐士医疗卫生用品(湖北)有限公司 | 一种抑菌避孕套 |
US20220168479A1 (en) * | 2019-08-21 | 2022-06-02 | Terumo Kabushiki Kaisha | Medical device and method for manufacturing same |
CN115043792A (zh) * | 2022-06-10 | 2022-09-13 | 首都医科大学 | 蓍草提取物、蓍草提取物单体化合物及其制备方法与应用 |
-
2023
- 2023-03-21 CN CN202310274339.XA patent/CN116474176A/zh active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5878747A (en) * | 1993-12-28 | 1999-03-09 | Fuji Latex Co., Ltd. | Condom coated with acidic polysaccharides |
CN1517326A (zh) * | 2002-07-12 | 2004-08-04 | 范崔生 | 栀子环烯醚萜总提物及其制备方法和用途 |
CN102846690A (zh) * | 2012-08-29 | 2013-01-02 | 江苏康宝医疗器械有限公司 | 阴道保健润滑液及其制备方法 |
CN103083733A (zh) * | 2013-02-19 | 2013-05-08 | 华熙福瑞达生物医药有限公司 | 一种医用体腔器械导入水性润滑剂 |
US20150264935A1 (en) * | 2014-03-19 | 2015-09-24 | Yi-Shou Chang | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same |
KR20170019183A (ko) * | 2015-08-11 | 2017-02-21 | (주)헵틸와이 | 산화 다당류 및 친수성 고분자 함유 코팅층을 포함하는 의료용 카테터 및 그 제조방법 |
CN106267381A (zh) * | 2016-07-12 | 2017-01-04 | 东莞市万佳医疗科技有限公司 | 体腔导入润滑液及其制备方法 |
CN105999426A (zh) * | 2016-07-26 | 2016-10-12 | 广东诺丝科技股份有限公司 | 一种透明质酸水溶性人体润滑液 |
CN108079385A (zh) * | 2017-12-20 | 2018-05-29 | 江苏省健尔康医用敷料有限公司 | 高均一性灭菌医用润滑剂 |
CN110393825A (zh) * | 2018-04-25 | 2019-11-01 | 北京为纳百川商贸有限公司 | 一种人体润滑液 |
CN109010932A (zh) * | 2018-08-23 | 2018-12-18 | 太仓怡泰霖智能科技有限公司 | 一种对妇科炎症有预防效果的热感水溶性人体润滑液 |
CN108785358A (zh) * | 2018-08-27 | 2018-11-13 | 维康腾达生物科技有限公司 | 一种金银花提取物的制备方法 |
US20220168479A1 (en) * | 2019-08-21 | 2022-06-02 | Terumo Kabushiki Kaisha | Medical device and method for manufacturing same |
CN112587294A (zh) * | 2020-12-31 | 2021-04-02 | 威乐士医疗卫生用品(湖北)有限公司 | 一种抑菌避孕套 |
CN115043792A (zh) * | 2022-06-10 | 2022-09-13 | 首都医科大学 | 蓍草提取物、蓍草提取物单体化合物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
浙江植物志编辑委员会编: "《浙江植物志 总论》", 31 December 1993, 浙江科学技术出版社, pages: 172 * |
罗达尚主编: "《新修晶珠本草》", 30 June 2004, 四川科学技术出版社, pages: 600 * |
陈长勋主编: "《中药药理学》", 31 January 2015, 上海科学技术出版社, pages: 97 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6995137B2 (en) | Water-soluble natural film and its preparing method | |
CN108158869A (zh) | 一种抑菌湿巾液、湿巾及其制备方法 | |
CN105199462A (zh) | 植物杀菌驱虫功能型内墙乳胶漆及其制备方法 | |
CN113248632A (zh) | 一种多功能中药有机酸接枝壳聚糖季铵盐广谱抗菌剂及其制备方法 | |
CN111346023A (zh) | 一种植物抑菌组合物及含该组合物的漱口水及其制备方法 | |
CN101766188A (zh) | 壳聚糖抗菌剂 | |
CN110840826A (zh) | 一种鼻阻隔剂及其制备方法 | |
Davis et al. | Bioactive hybrid composite membrane with enhanced antimicrobial properties for biomedical applications | |
JP6997710B2 (ja) | Myrsine africanaの抽出物を含む局所スキンケア組成物 | |
CN116474176A (zh) | 一种适用于人体自然腔道的润滑液及其应用 | |
CA2141193A1 (en) | Industrial, pharmaceutical and cosmetic applications for cultured plant cell gums | |
CN113956929A (zh) | 一种含左旋龙脑的复方冷制皂及其制备方法 | |
JP2010202604A (ja) | 皮膚常在菌正常化剤、皮膚常在菌正常化方法及びそれを用いる皮膚外用剤又は化粧料、並びにそれらの製造方法 | |
CN113855613A (zh) | 一种铁皮石斛牙膏及其制备方法 | |
CN111449187B (zh) | 一种布氏乳杆菌S-层蛋白修饰的香芹酚/β-环糊精脂质体及其制备方法和抗菌用途 | |
CN112245495A (zh) | 一种缓释抑菌凝胶及其制备方法 | |
CN111514175A (zh) | 一种免洗抗菌喷剂及其制备方法 | |
CN107802577A (zh) | 含有富勒烯天然纳米材料的育肤修肤美肤化妆品 | |
CN106137814B (zh) | 一种具有广谱抗菌作用的天然防腐剂 | |
KR100503035B1 (ko) | 폴리스티렌 황산염을 포함한 손세정제 | |
CN114762652B (zh) | 一种阴道凝胶及其制备方法 | |
CN107789277A (zh) | 一种具有多重功效的透明质酸唇部组合物及制备方法 | |
CN108309824A (zh) | 一种具有多重功效的透明质酸唇部组合物及制备方法 | |
Sumathi et al. | Anticariogenic effect of Vaccinium macrocarpon Aiton against causative organisms of dental caries | |
CN112336655A (zh) | 一种天然头皮护理剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |